A new FDA approval has given Pfizer a broader label for its respiratory syncytial virus (RSV) vaccine Abrysvo than rival ...

In conclusion, a demerger, like any major pivot, is a high-stakes, high-value moment where everything matters. Reconnect to ...

The pharmaceutical industry is undergoing a major transformation, placing patients at the forefront of drug development like ...

The UK medicines regulator approved Eli Lilly's Alzheimer's disease therapy Kisunla today, but the drug is too expensive to ...

Many will celebrate having an extra hour in bed – perhaps forgetting how they lost an hour at the end of March when the ...

Despite that cash windfall, Pfizer has "dramatically underperformed its peers and the market since 2019," according to ...

Pharma companies are moving their Generative AI (GenAI) investments from pilot to production through exploration, ...

Discussing Pfizer's platform, the lawmakers write that it "creates the impression that any patient interested in a particular ...

The increasing complexity of emerging therapies and the need for faster development have led to the adoption of advanced ...

Vyloy is the first CLDN18.2-targeting drug to reach the US market but has already been approved in Japan as well as in the EU ...

To learn more about the true value of AI and GenAI in pharma, pharmaphorum spoke with Sudip Chakraborty, Principal and Head ...

A study has shown that Roche's diabetic macular oedema (DME) therapy Vabysmo is effective in patients who identify as African ...